C3/C3a, Human, mAb 474

Quantity:
100 µg
Catalog #:
HM2073-100UG

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Monoclonal antibody 474 reacts with an epitope on C3a. The antibody reacts both with intact C3 as with C3a. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. During complement activation, C3 is proteolytically cleaved resulting in release of the anaphylatoxic peptide C3a. C3a is a small polypeptide consisting of 74 amino acids (ca.10kDa). C3a itself is very short-lived and in serum cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP) . C3a exerts its function through a specific receptor (C3aR), which belongs to the G-protein coupled receptor family. Expression of C3aR- has been reported in many cell types including myeloid and non-myeloid cells. Expression of C3aR on haematopoietic stem/progenitor cells has been shown to promote the trafficking/homing of these cells to the BM. Engagement of C3aR on DCs and T cells has been shown to up-regulate these cell functions.
C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported.
Specifications
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 μg/ml) 0.2 μm filtered protein G purified antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
Application Immuno assays, Western blot
Use Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Immunogen C3a
Isotype Mouse IgG1
Species Human
Alias Complement component 3
References 1. Hartmann, H et al; Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J Immunol Methods 1993, 166: 35
2. Stöve, S et al; Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. J Immunol Methods 1995, 182: 1
3. Li, R et al. Localized-statistical quantification of human serum proteome associated with type 2 diabetes. Plos one 2008, 3:e3224
4. Shi, L et al. Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome science 2009, 7:7
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Infectious diseases, Nephrology
Applications
Application: Immuno assays, Western blot
Application notes: W: diabetic serum proteins were separated on PAGE-gel and transferred to nitrocellulose
Use: Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Positive control: Human serum
Negative control: C3-deficient serum
References
References: 1. Hartmann, H et al; Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J Immunol Methods 1993, 166: 35
2. Stöve, S et al; Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. J Immunol Methods 1995, 182: 1
3. Li, R et al. Localized-statistical quantification of human serum proteome associated with type 2 diabetes. Plos one 2008, 3:e3224
4. Shi, L et al. Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome science 2009, 7:7
CoA-TDS HM1067-HM2099
pdf
(Size: 0.26 MB)
Protocol
pdf
(Size: 0.09 MB)